BioCentury-BayHelix China Healthcare Summit 2020

BioCentury and BayHelix Present the 7th China Healthcare Summit

The 7th BioCentury-BayHelix China Healthcare Summit provided an exclusive digital platform for C-suite executives and global investors to exchange information, meet virtually, and learn from industry KOLs – from China, Asia and the West.

For six years, the BioCentury-BayHelix China Healthcare Summit has been building the "Bridge to Innovation" in China. Now, challenged by COVID and facing global economic uncertainty and mounting geopolitical stress, where do China’s healthcare innovators go from here? And what are the implications for its international partners, investors and patients at home and abroad? The 7th Annual BioCentury-BayHelix China Healthcare Summit probes the key drivers of the next wave of biopharma and MedTech innovation in China.

View the 2020 Multi-Day Agenda

View the 2020 Speakers, Sponsors, Organizing Committee and Award Winners

Testimonials

“The healthcare industry has seen a wave of innovation and development since the COVID-19 pandemic. The new era, that comes with uncertainties and macroeconomic headwinds, requires CEOs, entrepreneurs, and all to communicate effectively and embrace innovation. BioCentury and BayHelix put together a high-quality program that really captures the latest industry trends and offers a valuable opportunity to connect with thought leaders in the region. We look forward to continuing to support the BioCentury-BayHelix China Healthcare Summit, as we have in the past, and sharing our insights at the event.”

Nisa Leung
Managing Partner
Qiming Venture Partners

"The BioCentury & BayHelix China Healthcare Summit has grown from strength to strength over the last eight years. It has become the reference China event for the biopharma community, with an increasingly global audience. As McKinsey, we are proud of our contribution to the Summit as Insights Partner, with our series of reports on “Building Bridges to Innovation”. We look forward to the ninth edition of the event. Given the current context around biotech and the biopharma industry, we expect the event to be once again a great gathering of minds to crystalize trends and shape the journey together."

Franck Le Deu
Senior Partner & Co-Leader of Asia Life Sciences Practice
McKinsey & Company